A prospective multi-center observational study. The study will enroll eligible subjects from the United States to optimize the biomarker panel and evaluate the performance of a cfDNA marker panel selected by the Sponsor for CRC and advanced adenoma detection.
This study is designed to prospectively collect blood samples and clinical data from subjects that have a suspected advanced adenoma or have been newly diagnosed with CRC scheduled for resection surgery, as well as subjects who are at average-risk of colorectal cancer and who are scheduled for routine colonoscopy examination. Subjects interested in participation and who meet inclusion criteria and provide written informed consent will be enrolled in the study. By accepting participation in the study, subjects will consent to provide up to 40 ml of blood at the study visit.
Study Type
OBSERVATIONAL
Enrollment
1,300
Evaluate the performance of a preliminary panel of biomarkers
Precision Recearch Institute
Chula Vista, California, United States
COMPLETEDPrecision Research Institute
San Diego, California, United States
Samples Collected for Plasma Circulating Free-DNA (cfDNA) Marker Testing
Samples Collected for Testing
Time frame: Within 12 months of sample collection
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Medical Associates Research Group
San Diego, California, United States
COMPLETEDClinical Research of California
Walnut Creek, California, United States
COMPLETEDCenter for Gastrointestinal Disorders
Hollywood, Florida, United States
COMPLETEDLakeland Regional Cancer Center
Lakeland, Florida, United States
RECRUITINGSpringfield Clinic
Springfield, Illinois, United States
RECRUITINGOchsner Clinic
New Orleans, Louisiana, United States
COMPLETEDDana Farber Cancer Institute
Boston, Massachusetts, United States
COMPLETEDMid Hudson Medical Research
New Windsor, New York, United States
RECRUITING...and 6 more locations